Steinbook R M, Goldstein B J, Brauzer B, Jacobson A F, Moreno S S
J Clin Pharmacol. 1975 Oct;15(10):700-4. doi: 10.1002/j.1552-4604.1975.tb05923.x.
Sixty newly admitted acute schizophrenic patients were randomly assigned to a double-blind trial of metiapine with a maximum dose of 450 mg per day versus a maximum dose of 450 mg per day versus a maximum daily dose of 900 mg chlorpromazine per day. At the conclusion of the study, 21 patients in each group showed marked to moderate improvement. There were significantly more marked improvers in the metiapine group then the chlorpromazine group on the Physician's Posttreatment Global Impression. Evaluation by analysis of covariance of the Brief Psychiatric Rating Scale showed a significant difference between treatment groups favoring chlorpromazine on the item of blunted affect. The spectrum of side effects was similar in the two groups, except for six patients treated with metiapine who displayed tachycardia on the EKG. This pulse elevation was reflected in the group data and is probably dose related. In conclusion, both drugs appeared to be equally efficacious in the treatment of newly admitted acute schizophrenic patients.
60名新收治的急性精神分裂症患者被随机分配到一项双盲试验中，一组使用甲硫平，最大剂量为每天450毫克，另一组使用氯丙嗪，最大日剂量为每天900毫克。在研究结束时，每组有21名患者显示出显著到中度的改善。在医生治疗后整体印象方面，甲硫平组显著改善的患者比氯丙嗪组更多。通过对简明精神病评定量表进行协方差分析评估发现，在情感迟钝项目上，治疗组之间存在显著差异，氯丙嗪组更具优势。两组的副作用谱相似，除了6名接受甲硫平治疗的患者心电图显示有心动过速。这种脉搏升高在组数据中有所体现，可能与剂量有关。总之，两种药物在治疗新收治的急性精神分裂症患者方面似乎同样有效。
